Risankizumab-Rzaa
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Risankizumab-Rzaa is used to treat psoriasis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $2.5 billion on Risankizumab-Rzaa across 122,000 claims for 37,000 beneficiaries.
Risankizumab-Rzaa is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $9565.60 to $22887.44 per ML — the most expensive product costs about 2.4× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$9565.60 – $22887.44
per ML
7d Activity
avg +0.3% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing RISANKIZUMAB-RZAA
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
SKYRIZI 150 MG/ML SYRINGE | $22887.4386 per ML | +0.57% |
SKYRIZI 150 MG/ML PEN | $22761.4629 per ML | +0.13% |
SKYRIZI 360 MG/2.4 ML ON-BODY | $9565.6005 per ML | +0.30% |
Frequently Asked Questions
What is Risankizumab-Rzaa used to treat?
Risankizumab-Rzaa is used to treat psoriasis, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Risankizumab-Rzaa?
In 2024, Medicare Part D spent $2.5 billion on Risankizumab-Rzaa across 122,000 claims for 37,000 beneficiaries.
How many Risankizumab-Rzaa products are on the market?
The Risankizumab-Rzaa drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Risankizumab-Rzaa?
NADAC reference prices for Risankizumab-Rzaa range from $9565.6005 to $22887.4386 per ML — the most expensive product costs about 2.4× the cheapest.
Which manufacturers make Risankizumab-Rzaa?
1 manufacturer lists Risankizumab-Rzaa in NADAC. Ranked by number of NDCs, the largest are AbbVie Inc. (3).
How has the price of Risankizumab-Rzaa changed recently?
Over the past 7 days, 3 Risankizumab-Rzaa NDCs rose and 0 fell, with a market-wide average change of +0.3%.